A New Push for Homegrown Medical Isotopes

Building America’s First Homegrown Mo-99 Facility

Eunice, New Mexico — A cutting-edge nuclear technology company based in Albuquerque is poised to revolutionize medical isotope production with a new facility near Eunice. The goal? To end the U.S.’s reliance on aging overseas reactors for Molybdenum-99 (Mo-99), the isotope critical for life-saving scans and cancer treatments.

Why This Matters

Currently, the U.S. imports 100% of its Mo-99 from reactors overseas—most of which are decades old. A single malfunction could disrupt supply chains, forcing hospitals to delay critical procedures. This new plant aims to eventually cover up to 50% of global Mo-99 demand, though its perishable nature demands just-in-time production—matching isotope creation with real-time medical use.

Beyond Mo-99: A Pipeline for Cancer Care

The facility won’t stop at Mo-99. Plans include producing 3.5 million doses of isotopes annually for cancer therapies, backed by over 90 clinical trials exploring next-gen treatments. Speed is non-negotiable: isotopes must reach patients within 36 hours of leaving the plant.

Challenges Ahead

• Regulatory Hurdles: Securing permits and compliance by 2030 is no small feat.
• Funding Crunch: The biggest obstacle—raising sufficient capital on schedule.
• Proven Tech, Reduced Risk: The project leverages established systems from a national lab to minimize technical failures.

The Big Picture

If successful, this facility could redefine U.S. medical supply chains, ensuring stability, security, and self-sufficiency in a sector where delays can cost lives.

--- _{For updates on this project, follow industry developments as the 2030 deadline approaches.}